Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• This invention relates to substituted [1,6]-naphthyridines that inhibit SYK kinase.
• this invention relates to a novel class of substituted [1,6]-naphthyridines and pharmaceutical compositions comprising these compounds.
• This invention also relates to methods for producing such novel [1,6]-naphthyridines. Because of the ability of these compounds to inhibit SYK kinase, the compounds and pharmaceutical compositions of this invention are particularly well suited for preventing and treating inflammatory and allergic diseases.
• mediators include histamine, proteases, leukotrienes and cytokines.
• mediators cause increased vascular permeability, mucus production, bronchoconstriction, tissue degradation and inflammation, thus playing key roles in the etiology and symptoms of asthma and allergic disorders.
• SYK kinase acts as a central initiator of all subsequent signaling leading to mediator release.
• the critical role of SYK kinase in the signaling path was demonstrated by the complete inhibition of mediator release by a protein containing the SH2 domains of SYK kinase that functioned as an inhibitor of SYK kinase (J. A. Taylor et al., Molec. and Cell Biol., 1995, 15, 4149).
• ER-27319 (3,4-dimethyl-10-(3-aminopropyl)-9-acridone oxalate), a compound reported to interfere with the activation of SYK, has been shown to inhibit anti-IgE mediated degranulation in rodent and human mast cells (K. Moriya et al., Proc. Nat. Acad. Sci. USA, 1997, 94, 12539).
• SYK kinase activation and activity is required for Fc ⁇ RI-mediated release of mediators from mast cells. Therefore, agents that block the activity of SYK kinase act to block the release of allergic and pro-inflammatory mediators and cytokines. These agents have potential utility in treating inflammatory and allergic disorders including asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), ulcerative colitis, Crohn's disease, bronchitis, conjunctivitis, psoriasis, scleroderma, urticaria, dermatitis and allergic rhinitis.
• COPD chronic obstructive pulmonary disease
• ARDS adult respiratory distress syndrome
• ulcerative colitis Crohn's disease
• bronchitis conjunctivitis
• psoriasis scleroderma
• urticaria dermatitis and allergic rhinitis.
• WO 0109134 discloses purine derivatives as inhibitors of SYK kinase.
• WO 9931073 describes pyrimidine-5-carboxamide derivatives as inhibitors of SYK kinase.
• WO 0147922 describes substituted azaindoles useful in the treatment of disease states capable of being modulated by the inhibition of protein kinases, in particular SYK kinase.
• WO 9818782 describes inhibitors of ZAP70 that are also reported to inhibit SYK.
• B cells In addition to mast cells, SYK is expressed in other hematopoietic cells including B cells, where it is thought to play an essential role in transducing signals required for the transition of immature B cells into mature recirculating B cells (M. Turner et al., Immunology Today, 2000, 21, 148). B cells are reported to play an important role in some inflammatory conditions such as lupus (O. T. Chan et al., Immunological Rev., 1999, 169, 107) and rheumatoid arthritis (A. Gause and C. Borek, Biodrugs, 2001, 15, 73).
• SYK was also reported to be an element of the signaling cascade in beta-amyloid and prion fibrils leading to production of neurotoxic products (C. K. Combs et al., J. Neurosci., 1999, 19, 928). Furthermore, an inhibitor of SYK blocked the production of these neurotoxic products. Thus a SYK inhibitor would potentially be useful in the treatment of Alzheimer's disease and related neuroinflammatory diseases.
• Another report (Y. Kuno et al., Blood, 2001, 97, 1050) demonstrates that SYK plays an important role in malignant progression. A TEL-SYK fusion protein was found to transform hematopoietic cells suggesting a role in the pathogenesis of hematopoietic malignancies. Therefore a SYK inhibitor may be useful in the treatment of certain types of cancers.
• SYK is a mediator of epithelial cell growth and suggests that it could be a potential tumor-suppressor in human breast carcinomas (P. J. P. Coopman et al., Nature, 2000, 406, 742).
• SYK kinase activity could be desirable for treatment of inflammatory and allergic disease and asthma, a complete, irreversible blockade of SYK kinase activity may not be desirable.
• BE 835,770 describes 5-amino-1,6-naphthyridines having antimicrobial activity.
• U.S. Pat. No. 3,928,367, U.S. Pat. No. 4,017,500, U.S. Pat. No. 4,115,395 and U.S. Pat. No. 4,260,759 describe 5-amino-1,6-naphthyridines having antifungal and antibacterial activity.
• WO 9918077 describes 5-piperazinyl-1,6-naphthyridines as serotonin antagonists.
• COPD chronic obstructive pulmonary disease
• ARDS adult respiratory distress syndrome
• ulcerative colitis Crohn's disease
• bronchitis conjunctivitis
• psoriasis scleroderma
• urticaria dermatitis allergic rhinitis
• lupus and rheumatoid arthritis using the novel compounds of the invention.
• R 3 is H, C 1-3 alkyl, halogen or phenyl
• R 5 is N(R 9 )(R 10 ) or OR 11 , wherein
• R 9 is H or C 1-3 alkyl
• R 10 is aminoC 2-6 alkyl, C 1-4 alkylaminoC 2-6 alkyl, diC 1-4 alkylaminoC 2-6 alkyl, C 1-4 alkoxyC 2-6 alkyl or hydroxyC 2-6 alkyl, wherein one methylene group in said C 2-6 alkyl is optionally replaced with an oxygen, sulfur, NH, or NCH 3 , and wherein each methylene group in said C 2-6 alkyl is optionally substituted with a halogen, cyano or hydroxy group, or R 10 is C 3-7 cycloalkyl, heterocycloalkyl, heteroaryl, C 3-7 cycloalkylC 1-4 alkyl, heterocycloalkylC 1-4 alkyl, arylC 1-4 alkyl or heteroarylC 1-4 alkyl each optionally substituted with one or more C 1-4 alkyl, amino, C 1-4 alkylamino, diC 1-4 alkylamino, aminoC 1-3 alkyl
• R 11 is aminoC 2-6 alkyl, C 1-4 alkylaminoC 2-6 alkyl, diC 1-4 alkylamninoC 2-6 alkyl, C 1-4 alkoxyC 2-6 alkyl or hydroxyC 2-6 alkyl, wherein one methylene group in said C 2-6 alkyl is optionally replaced with an oxygen, sulfur, NH, or NCH 3 , and wherein each methylene group in said C 2-6 alkyl is optionally substituted with a halogen, cyano or hydroxy group, or R 11 is C 3-7 cycloalkyl, heterocycloalkyl, heteroaryl, C 3-7 cycloalkylC 1-4 alkyl, heterocycloalkylC 1-4 alkyl, arylC 1-4 alkyl or heteroarylC 1-4 alkyl each optionally substituted with one or more C 1-4 alkyl, amino, C 1-4 alkylamino, diC 1-4 alkylamino, aminoC 1-3 al
• R 7 is phenyl, naphthyl, furyl, thienyl, pyridyl, indolyl, benzothiazolyl or pyrrolyl optionally substituted with one or more C 1-3 alkoxy, halogen, CF 3 , CF 3 O, hydroxy, C 1-3 alkyl, amino, C 1-3 alkylamino, diC 1-3 alkylamino, C 1-3 alkylaminoC 1-3 alkyl, diC 1-3 alkylaminoC 1-3 alkyl, (C 1-3 alkylaminoC 1-3 alkyl)(C 0-3 alkyl)amino, (diC 1-3 alkylaminoC 1-3 alkyl)(C 0-3 alkyl)amino, C 1-3 alkylthio, aminocarboxy, C 1-3 alkylcarbonyl, ureido optionally substituted with C 1-3 alkyl, C(O)OC 1-4 alkyl,
• R 8 is H, halogen or cyano.
• R 3 is H or methyl
• R 5 is N(R 9 )(R 10 ) or OR 11 wherein
• R 9 is H or methyl
• R 10 is aminoC 2-6 alkyl, C 1-4 alkylaminoC 2-6 alkyl, diC 1-4 alkylaminoC 2-6 alkyl, C 1-4 alkoxyC 2-6 alkyl or hydroxyC 2-6 alkyl, wherein one methylene group in said C 2-6 alkyl is optionally replaced with an oxygen, sulfur, NH, or NCH 3 , and wherein each methylene group in said C 2-6 alkyl is optionally substituted with a halogen, cyano or hydroxy group, or R 10 is C 4-7 cycloalkyl, heterocycloalkyl selected from pyrrolidinyl and piperidinyl, heteroaryl selected from oxazolyl, isoxazolyl, pyridyl and pyrimidinyl, C 3-6 cycloalkylC 1-4 alkyl, heterocycloalkylC 1-4 alkyl wherein said heterocycloalkyl is selected from morpholinyl, pyr
• R 11 is is aminoC 2-6 alkyl, C 1-4 alkylaminoC 2-6 alkyl, diC 1-4 alkylaminoC 2-6 alkyl, C 1-4 alkoxyC 2-6 alkyl or hydroxyC 2-6 alkyl, wherein one methylene group in said C 2-6 alkyl is optionally replaced with an oxygen, sulfur, NH, or NCH 3 , and wherein each methylene group in said C 2-6 alkyl is optionally substituted with a halogen, cyano or hydroxy group, or R 11 is C 5-7 cyclohexyl, heterocycloalkyl selected from pyrrolidinyl and piperidinyl, heteroaryl selected from oxazolyl, isoxazolyl, pyridyl and pyrimidinyl, C 3-6 cycloalkylC 1-4 alkyl, heterocycloalkylC 1-4 alkyl wherein said heterocycloalkyl is selected from morpholinyl,
• R 7 is phenyl, naphthyl, furyl, thienyl, pyridyl, indolyl, benzothiazolyl or pyrrolyl optionally substituted with one or more C 1-3 alkoxy, halogen, CF 3 , CF 3 O, hydroxy, C 1-3 alkyl, amino, C 1-3 alkylamino, diC 1-3 alkylamino, C 1-3 alkylaminoC 1-3 alkyl, diC 1-3 alkylaminoC 1-3 alkyl, (C 1-3 alkylaminoC 1-3 alkyl)(C 0-3 alkyl)amino, (diC 1-3 alkylaminoC 1-3 alkyl)(C 0-3 alkyl)amino, C 1-3 alkylthio, aminocarboxy, ureido optionally substituted with C 1-3 alkyl, acetamido or heterocycloalkyl groups, or with a phen
• R 5 is N(R 9 )(R 10 ) or OR 11 wherein
• R 9 is H or methyl
• R 10 is aminoC 2-6 alkyl, methylaminoC 2-6 alkyl, dimethylaminoC 2-6 alkyl, methoxyC 2-6 alkyl or hydroxyC 2-6 alkyl, or hydroxyC 2-6 alkyl, wherein one methylene group in said C 2-6 alkyl is optionally replaced with an oxygen or sulfur, and wherein each methylene group in said C 2-6 alkyl is optionally substituted with a hydroxy group, or R 10 is C 4-7 cycloalkyl, heterocycloalkyl selected from pyrrolidinyl and piperidinyl, heteroaryl selected from oxazolyl, isoxazolyl, pyridyl and pyrimidinyl, C 3-6 cycloalkylC 1-4 alkyl, heterocycloalkylC 1-4 alkyl wherein said heterocycloalkyl is selected from, pyrrolidin-2-onyl and piperidinyl, benzyl or heteroary
• R 11 is aminoC 2-6 alkyl, methylaminoC 2-6 alkyl, dimethylaminoC 2-6 alkyl, methoxyC 2-6 alkyl or hydroxyC 2-6 alkyl, wherein one methylene group in said C 2-6 alkyl is optionally replaced with an oxygen or sulfur, and wherein each methylene group in said C 2-6 alkyl is optionally substituted with a hydroxy group, or R 11 is C 5-7 cycloalkyl, heterocycloalkyl selected from pyrrolidinyl and piperidinyl, heteroaryl selected from oxazolyl, isoxazolyl, pyridyl and pyrimidinyl, C 3-6 cycloalkylC 1-4 alkyl, heterocycloalkylC 1-4 alkyl wherein said heterocycloalkyl is selected from, pyrrolidin-2-onyl and piperidinyl, benzyl or heteroarylC 1-4 alkyl wherein said
• R 7 is phenyl, optionally substituted in the 3-, 4-or 5-positions with one or more methoxy, fluorine, chlorine, bromine, CF 3 , CF 3 O, C 1-3 alkyl, diC 1-3 alkylamino, diC 1-3 alkylaminoC 1-3 alkyl, (C 1-3 alkylaminoC 1-3 alkyl)(C 0-3 alkyl)amino, (diC 1-3 alkylaminoC 1-3 alkyl)(C 0-3 alkyl)amino, thiomethoxy, acetamido, 4-morpholinyl, 1-piperidinyl or 1-pyrrolidinyl groups, or substituted in the 4-position with a phenyl group optionally substituted in the 4-position with a methyl, methoxy, 2-thienyl or 3-pyridyl group, or R 7 is a 2-naphthyl or 2-thienyl group or a 5-indo
• R 8 is H.
• R 3 is H
• R 5 is N(R 9 )(R 10 ) or OR 11 wherein
• R 9 is H or methyl
• R 10 is aminoC 3-4 alkyl or hydroxyC 3-4 alkyl wherein each methylene group in said C 3-4 alkyl is optionally substituted with a hydroxy group, or R 10 is C 5-7 cycloalkyl substituted with an amino or hydroxy group, and
• R 11 is aminoC 3-4 alkyl or hydroxyC 3-4 alkyl wherein each methylene group in said C 3-4 alkyl is optionally substituted with a hydroxy group, or R 11 is C 5-7 cycloalkyl substituted with an amino or hydroxy group;
• R 7 is phenyl, substituted in the 4-position with a diC 1-2 alkylamino, (dimethylaminoC 2-3 alkyl)(C 0-3 alkyl)amino, isopropyl, 4-morpholinyl, 4-piperidinyl or 4-pyrrolidinyl group and optionally substituted in the 3-position with a chlorine, bromine or methoxy group; and
• R 8 is H.
• the invention includes pharmaceutically acceptable derivatives of compounds of formula (I).
• a “pharmaceutically acceptable derivative” refers to any pharmaceutically acceptable acid, salt or ester of a compound of this invention, or any other compound which, upon administration to a patient, is capable of providing (directly or indirectly) a compound of this invention, a pharmacologically active metabolite or pharmacologically active residue thereof.
• Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases.
• suitable acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic and benzenesulfonic acids.
• Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N—(C 1 -C 4 alkyl) 4 + salts.
• the compounds of this invention include prodrugs of compounds of the formula (I).
• Prodrugs include those compounds that, upon simple transformation, are modified to produce the compounds of the invention. Simple chemical transformations include hydrolysis, oxidation and reduction which occur enzymatically, metabolically or otherwise. Specifically, when a prodrug of this invention is administered to a patient, the prodrug may be transformed into a compound of formula (I), thereby imparting the desired pharmacological effect.
• Any compounds of this invention containing one or more asymmetric carbon atoms may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included in the present invention.
• Each stereogenic carbon may be in the R or S configuration, or a combination of configurations.
• Some of the compounds of the invention can exist in more than one tautomeric form.
• the invention includes all such tautomers.
• the compounds of the invention are only those which are contemplated to be ‘chemically stable’ as will be appreciated by those skilled in the art.
• a compound which would have a ‘dangling valency’, or a ‘carbanion’ are not compounds contemplated by the invention.
• BuOH is butanol
• DMF is dimethylformamide
• DMSO dimethyl sulfoxide
• EtOAc is ethyl acetate
• EtOH is ethanol
• HPLC is high-performance liquid chromatography
• LDA is lithium diisopropylamide
• MeOH is methanol
• THF is tetrahydrofuran
• alkyl refers to a saturated aliphatic radical containing from one to ten carbon atoms or a mono- or polyunsaturated aliphatic hydrocarbon radical containing from two to twelve carbon atoms unless otherwise stated.
• the mono- or polyunsaturated aliphatic hydrocarbon radical contains at least one double or triple bond, respectively.
• Alkyl refers to both branched and unbranched alkyl groups. Examples of “alkyl” include alkyl groups which are straight chain alkyl groups containing from one to eight carbon atoms and branched alkyl groups containing from three to ten carbon atoms.
• alkyl groups which are straight chain alkyl groups containing from one to six carbon atoms and branched alkyl groups containing from three to six carbon atoms.
• alk or “alkyl” prefix refers to analogs according to the above definition of “alkyl”.
• alkoxy refers to alkyl groups linked to a second group via an oxygen or sulfur atom.
• alkanoyl refers to an alkyl group linked to a carbonyl group (C ⁇ O).
• Each alkyl or alkyl analog described herein shall be understood to be optionally partially or fully halogenated.
• cycloalkyl refers to the cyclic analog of an alkyl group, as defined above.
• examples of cycloalkyl groups are saturated or unsaturated nonaromatic cycloalkyl groups containing from three to eight carbon atoms, and other examples include cycloalkyl groups having three to six carbon atoms.
• heterocycloalkyl refers to a stable 4-8 membered (but preferably, 5 or 6 membered) monocyclic or 8-11 membered bicyclic heterocycle radical which may be either saturated or unsaturated, and is non-aromatic.
• Each heterocycle consists of carbon atoms and from 1 to 4 heteroatoms chosen from nitrogen, oxygen and sulfur.
• the heterocycle may be attached by any atom of the cycle, which results in the creation of a stable structure.
• heterocycloalkyl examples include radicals such as pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, azetidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuranyl, hexahydropyrimidinyl, hexahydropyridazinyl, dihydro-oxazolyl, 1,2-thiazinanyl-1,1-dioxide, 1,2,6-thiadiazinanyl-1,1-dioxide, isothiazolidinyl-1,1-dioxide and imidazolidinyl-2,4-dione.
• halogen refers to bromine, chlorine, fluorine or iodine.
• aryl shall be understood to mean a 6-12 membered aromatic carbocycle, which can be a single ring or can be multiple rings fused together or linked covalently.
• aryl includes, for example, phenyl and naphthyl; other terms comprising “aryl” will have the same definition for the aryl component, examples of these moieties include: arylalkyl, aryloxy or arylthio.
• heteroaryl refers to a stable 5-8 membered (but preferably, 5 or 6 membered) monocyclic or 8-11 membered bicyclic aromatic heterocycle radical.
• Each heterocycle consists of carbon atoms and from 1 to 4 heteroatoms chosen from nitrogen, oxygen and sulfur.
• the heteroaryl group may be attached by any atom of the ring which results in the creation of a stable structure.
• heteroaryl examples include radicals such as furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, indolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, purinyl, quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl,
• nitrogen and sulfur include any oxidized form of nitrogen and sulfur and the quatemized form of any basic nitrogen.
• the invention additionally provides for methods for making the compounds of the formula (I).
• the compounds of the invention may be prepared by the general methods and examples presented below, and methods known to those of ordinary skill in the art.
• Reaction progress may be monitored by conventional methods such as thin layer chromatography (TLC).
• TLC thin layer chromatography
• Intermediates and products may be purified by methods known in the art, including column chromatography, HPLC or recrystallization.
• a 2-methylnicotinic acid derivative (II) is treated with a strong base such as lithium diisopropylamide (LDA) in a suitable solvent such as THF at about ⁇ 78° C. to 0° C. to form the dianion.
• a strong base such as lithium diisopropylamide (LDA)
• a suitable solvent such as THF
• a nitrile bearing the desired R 7 preferably at about ⁇ 78° C., and allowing the reaction to warm to about room temperature until reaction is complete to provide the [1,6]-naphthyridin-5-ol (III), which may also exist as the tautomeric 6H-[1,6]-naphthyridin-5-one (IIIa).
• the [1,6]-naphthyridin-5-ol is then treated with a suitable halogenating agent.
• a suitable halogenating agent for example, treatment with POCl 3 , optionally in the presence of a suitable base such as N,N-diethylaniline, at a temperature of about 0° C. to 140° C., preferably at about 100° C. to 135° C., provides the 5chloro-[1,6]-naphthyridine IV.
• This may then be reacted with an excess of the desired amine (R′NH 2 ) at a suitable temperature, preferably about 100° C. to 140° C., optionally in a sealed reaction vessel, to provide a compound of formula (I) having an amine at R 5 .
• a compound of formula (I) having an ether link at R 5 is desired, one may react IV with the desired alcohol (R′OH), in the presence of a suitable base such as sodium hydride in a suitable solvent such as DMF at a temperature of about 0° C. to 100° C., preferably at about room temperature.
• a suitable base such as sodium hydride
• a suitable solvent such as DMF
• a carbanion is reacted with a 2-halonicotinic acid, preferably a 2-chloro- or 2-bromonicotinic acid, (VI), in the presence of a copper catalyst, preferably copper acetate, to give a 2-(2-substituted-2-oxo-ethyl)nicotinic acid intermediate (VIII).
• the carbanion may be generated from a 1,3-dicarbonyl compound such as VII, and a base, preferably sodium ethoxide.
• intermediate VIII may be treated with aqueous acid, such as aqueous sulfuric acid, at about room temperature to provide a pyrano[4,3-b]pyridin-5-one (IX). This may then be treated with ammonia in a suitable solvent such as ethanol, at a suitable temperature, preferably about the reflux temperature, to provide III.
• aqueous acid such as aqueous sulfuric acid
• a suitable solvent such as ethanol
• 7-Aryl-5-amino-[1,6]naphthyridines may be made by the procedure described in Examples 1-3 below (Methods A-C).
• Methods A-C Methods A-C
• aryl nitrile Example 1
• appropriately substituted amine Example 3
• alcohol Example 11
• one may obtain a precursor of the desired compound which may be further modified synthetically by methods known to those skilled in the art to obtain the desired compound of formula (I).
• Examples 4-13 are illustrative of procedures that may be used to modify intermediates to obtain desired compounds of the invention.
• This example is representative of a procedure using a Suzuki reaction carried out on a resin-bound intermediate. This procedure may be used to prepare compounds with a substituted biphenyl in the 7-position.
• the cyano group may be modified by methods known in the art to obtain additional substituents in the 8-position. Intermediates may be converted to compounds of formula (I) by Methods B and C.
• a solution of LDA (2.4 mmol) was prepared by adding n-BuLi (1.7 mL, 2.4 mmol, 1.4 M in hexanes) via syringe to a solution of diisopropylamine (247 mg, 2.4 mmol) in THF (10 mL) at 0° C. and stirring for 15 minutes. The solution was then cooled to ⁇ 40° C., then 2-methyl-6-trifluoromethylnicotinic acid (250 mg, 1.2 mmol) in THF (5 mL) was added via syringe. After stirring at ⁇ 40° C.
• a solution of NaOEt (0.6 mmol) was prepared by adding Na (15 mg, 0.6 mmol) to EtOH (5 mL) and stirring at room temperature for 30 minutes.
• 1-(4-Methoxyphenyl)-butane-1,3-dione (121 mg, 0.6 mmol) was added and the mixture was stirred at room temperature for 15 minutes.
• 5-bromo-2-chloronicotinic acid (100 mg, 0.4 mmol) and CuOAc (10 mg, catalytic) was added. The mixture was then heated to reflux for 4 hours. The mixture was cooled to room temperature and quenched by addition of HOAc (0.5 mL).
• the product was purified on a preparatory TLC plate, providing ⁇ 3-[5-(3-aminopropylamino)-7-(4-methoxyphenyl)-[1,6]naphthyridin-2-ylamino]-propyl ⁇ -carbamic acid tert-butyl ester (53 mg, 99%).
• SYK was purified as a GST-fusion protein.
• the kinase activity was measured using DELFIA (Dissociation Enhanced Lanthanide Fluoroimmunoassay) which utilizes europium chelate-labeled anti-phosphotyrosine antibodies to detect phosphate transfer to a random polymer, poly Glu 4 : Tyr 1 (PGTYR).
• DELFIA Dissociation Enhanced Lanthanide Fluoroimmunoassay
• the kinase assay was performed in kinase assay buffer (50 mM HEPES, pH 7.0, 25 mM MgCl 2 , 5 mM MnCl 2 , 50 mM KCl, 100 ⁇ M Na 3 VO 4 , 0.2% BSA, 0.01% CHAPS).
• Test samples initially dissolved in DMSO at 1 mg/mL, were pre-diluted for dose response (11 doses with starting final concentration of 30 ⁇ g/mL, 1 to 3.5 serial dilutions) with the assay buffer in 96-well polypropylene microtiter plates. A 25 ⁇ L aliquot of this diluted sample was added to neutravidin coated 96-well white plate (PIERCE).
• the compounds of the invention are useful in inhibiting the activity of SYK kinase. In doing so, these compounds are useful in blocking disease processes mediated by SYK kinase.
• Compounds of the invention effectively block activation of mast cells by inhibiting SYK kinase. This in turn prevents the release of inflammatory mediators including histamine, proteases, leukotrienes and cytokines. These mediators play a key role in the etiology of allergic and inflammatory disorders. Preventing the release of these mediators is a desirable means for treating these conditions. Thus there are provided methods for treating these conditions using the compounds of the invention.
• inflammatory and allergic conditions involving mast cell activation include asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), ulcerative colitis, Crohn's disease bronchitis, conjunctivitis, psoriasis, scleroderma, urticaria, dermatitis and allergic rhinitis.
• COPD chronic obstructive pulmonary disease
• ARDS adult respiratory distress syndrome
• ulcerative colitis Crohn's disease bronchitis
• conjunctivitis conjunctivitis
• psoriasis scleroderma
• urticaria dermatitis
• allergic rhinitis allergic rhinitis
• B cells contribute to the etiology of the disease
• the compounds of the invention can also be used to treat other disorders associated with inappropriate mast cell or B cell activation, unrelated to those listed above or discussed in the Background of the Invention. Therefore, the invention also provides methods of treating allergic and inflammatory diseases comprising
• the compounds of the invention may be administered in any conventional dosage form in any conventional manner.
• Routes of administration include, but are not limited to, intravenously, intramuscularly, subcutaneously, intrasynovially, by infusion, sublingually, transdermally, orally, topically or by inhalation.
• the preferred modes of administration are oral and intravenous.
• Compositions comprising the compounds of the invention for each of the aforementioned routes of administration will be apparent to the skilled artisan.
• the invention also provides for pharmaceutical compositions including a therapeutically effective amount of the compounds according to the invention.
• Such pharmaceutical compositions will include pharmaceutically acceptable carriers and adjuvants as further described below.
• the compounds of this invention may be administered alone or in combination with adjuvants that enhance stability of the inhibitors, facilitate administration of pharmaceutical compositions containing them in certain embodiments, provide increased dissolution or dispersion, increase inhibitory activity, provide adjunct therapy, and the like, including other active ingredients.
• combination therapies utilize lower dosages of the conventional therapeutics, thus avoiding possible toxicity and adverse side effects incurred when those agents are used as monotherapies.
• Compounds of the invention may be physically combined with the conventional therapeutics or other adjuvants into a single pharmaceutical composition.
• the compounds may then be administered together in a single dosage form.
• the pharmaceutical compositions comprising such combinations of compounds contain at least about 15%, but more preferably at least about 20%, of a compound of the invention (w/w) or a combination thereof.
• the compounds may be administered separately (either serially or in parallel). Separate dosing allows for greater flexibility in the dosing regime.
• dosage forms of the compounds of this invention include pharmaceutically acceptable carriers and adjuvants known to those of ordinary skill in the art.
• carriers and adjuvants include, for example, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, buffer substances, water, salts or electrolytes and cellulose-based substances.
• Preferred dosage forms include, tablet, capsule, caplet, liquid, solution, suspension, emulsion, lozenges, syrup, reconstitutable powder, granule, suppository and transdermal patch. Methods for preparing such dosage forms are known (see, for example, H. C. Ansel and N. G.
• Dosage levels and requirements are well-recognized in the art and may be selected by those of ordinary skill in the art from available methods and techniques suitable for a particular patient. In some embodiments, dosage levels range from about 10-1000 mg/dose for a 70 kg patient. Although one dose per day may be sufficient, up to 5 doses per day may be given. For oral doses, up to 2000 mg/day may be required. As the skilled artisan will appreciate, lower or higher doses may be required depending on particular factors. For instance, specific dosage and treatment regimens will depend on factors such as the patient's general health profile, the severity and course of the patient's disorder or disposition thereto, and the judgment of the treating physician.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (6)

Applications Claiming Priority (1)

Related Child Applications (1)

Publications (1)

Family

ID=21850483

Family Applications (4)

Family Applications After (3)

Country Status (3)

Cited By (16)

Families Citing this family (36)

Citations (11)

Family Cites Families (7)

• 2001
  • 2001-12-21 US US10/029,714 patent/US20030158195A1/en not_active Abandoned
• 2002
  • 2002-12-03 AU AU2002357773A patent/AU2002357773A1/en not_active Abandoned
  • 2002-12-03 WO PCT/US2002/038375 patent/WO2003057695A1/fr not_active Ceased
• 2003
  • 2003-04-15 US US10/413,980 patent/US7321041B2/en not_active Expired - Lifetime
• 2008
  • 2008-01-15 US US12/014,190 patent/US7678911B2/en not_active Expired - Lifetime
• 2009
  • 2009-03-06 US US12/399,292 patent/US7705151B2/en not_active Expired - Lifetime

Patent Citations (11)

Also Published As

Similar Documents

Legal Events